← Evidence map

ArticleTranslational lung cancer research2026

Efficacy and safety of osimertinib combined with anlotinib in EGFR-mutant non-squamous non-small cell lung cancer with gradual progression after first-line osimertinib therapy: a single-center retrospective cohort study.

Li Hao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Efficacy and safety of osimertinib combined with anlotinib in EGFR-mutant non-squamous non-small cell lung cancer with gradual progression after first-line osimertinib therapy: a single-center retrospective cohort study. | OpenQuestion